Sutro Biopharma, Inc. Stock News
$0.87
0.75%
yesterday
Nasdaq,
Sep 30, 10:17 pm CET
Sutro Biopharma, Inc. Stock News
Neutral
GlobeNewsWire
●
one day ago
– Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced an organizational restructuring to prioritize the advancement of its three ADC programs and research and developme...
Neutral
GlobeNewsWire
●
about 2 months ago
– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 –
Neutral
GlobeNewsWire
●
5 months ago
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization -
Neutral
GlobeNewsWire
●
5 months ago
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences.
Neutral
GlobeNewsWire
●
5 months ago
- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - - Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile -
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
